Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

The dietary isothiocyanate sulforaphane modulates gene expression and alternative gene splicing in a PTEN null preclinical murine model of prostate cancer

Authors: Maria H Traka, Caroline A Spinks, Joanne F Doleman, Antonietta Melchini, Richard Y Ball, Robert D Mills, Richard F Mithen

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

Dietary or therapeutic interventions to counteract the loss of PTEN expression could contribute to the prevention of prostate carcinogenesis or reduce the rate of cancer progression. In this study, we investigate the interaction between sulforaphane, a dietary isothiocyanate derived from broccoli, PTEN expression and gene expression in pre malignant prostate tissue.

Results

We initially describe heterogeneity in expression of PTEN in non-malignant prostate tissue of men deemed to be at risk of prostate cancer. We subsequently use the mouse prostate-specific PTEN deletion model, to show that sulforaphane suppresses transcriptional changes induced by PTEN deletion and induces additional changes in gene expression associated with cell cycle arrest and apoptosis in PTEN null tissue, but has no effect on transcription in wild type tissue. Comparative analyses of changes in gene expression in mouse and human prostate tissue indicate that similar changes can be induced in humans with a broccoli-rich diet. Global analyses of exon expression demonstrated that sulforaphane interacts with PTEN deletion to modulate alternative gene splicing, illustrated through a more detailed analysis of DMBT1 splicing.

Conclusion

To our knowledge, this is the first report of how diet may perturb changes in transcription induced by PTEN deletion, and the effects of diet on global patterns of alternative gene splicing. The study exemplifies the complex interaction between diet, genotype and gene expression, and the multiple modes of action of small bioactive dietary components.
Appendix
Available only for authorised users
Literature
1.
Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H: Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci USA. 2006, 103: 1480-1485. 10.1073/pnas.0510652103PubMedCentralCrossRefPubMed
2.
Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM: A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009, 461: 495-500. 10.1038/nature08361PubMedCentralCrossRefPubMed
3.
Keum YS, Khor TO, Lin W, Shen G, Kwon KH, Barve A, Li W, Kong AN: Pharmacokinetics and pharmacodynamics of broccoli sprouts on the suppression of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: implication of induction of Nrf2, HO-1 and apoptosis and the suppression of Akt-dependent kinase pathway. Pharm Res. 2009, 26: 2324-2331. 10.1007/s11095-009-9948-5CrossRefPubMed
4.
Singh SV, Warin R, Xiao D, Powolny AA, Stan SD, Arlotti JA, Zeng Y, Hahm ER, Marynowski SW, Bommareddy A: Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. Cancer Res. 2009, 69: 2117-2125. 10.1158/0008-5472.CAN-08-3502PubMedCentralCrossRefPubMed
5.
Singh AV, Xiao D, Lew KL, Dhir R, Singh SV: Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. Carcinogenesis. 2004, 25: 83-90. 10.1093/carcin/bgg178CrossRefPubMed
6.
Juge N, Mithen RF, Traka M: Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci. 2007, 64: 1105-1127. 10.1007/s00018-007-6484-5CrossRefPubMed
7.
Chambers KF, Bacon JR, Kemsley EK, Mills RD, Ball RY, Mithen RF, Traka MH: Gene expression profile of primary prostate epithelial and stromal cells in response to sulforaphane or iberin exposure. Prostate. 2009, 69: 1411-1421. 10.1002/pros.20986CrossRefPubMed
8.
Barve A, Khor TO, Hao X, Keum YS, Yang CS, Reddy B, Kong AN: Murine prostate cancer inhibition by dietary phytochemicals--curcumin and phenyethylisothiocyanate. Pharm Res. 2008, 25: 2181-2189. 10.1007/s11095-008-9574-7PubMedCentralCrossRefPubMed
9.
Joseph MA, Moysich KB, Freudenheim JL, Shields PG, Bowman ED, Zhang Y, Marshall JR, Ambrosone CB: Cruciferous vegetables, genetic polymorphisms in glutathione s-transferases m1 and t1, and prostate cancer risk. Nutr Cancer. 2004, 50: 206-213. 10.1207/s15327914nc5002_11CrossRefPubMed
10.
Kristal AR, Lampe JW: Brassica vegetables and prostate cancer risk: A review of the epidemiological evidence. Nutrition and Cancer-an International Journal. 2002, 42: 1-9. 10.1207/S15327914NC421_1.CrossRef
11.
Steinbrecher A, Nimptsch K, Husing A, Rohrmann S, Linseisen J: Dietary glucosinolate intake and risk of prostate cancer in the EPIC-Heidelberg cohort study. Int J Cancer. 2009, 125: 2179-2186. 10.1002/ijc.24555CrossRefPubMed
12.
Kirsh VA, Peters U, Mayne ST, Subar AF, Chatterjee N, Johnson CC, Hayes RB: Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst. 2007, 99: 1200-1209. 10.1093/jnci/djm065CrossRefPubMed
13.
Traka M, Gasper AV, Melchini A, Bacon JR, Needs PW, Frost V, Chantry A, Jones AM, Ortori CA, Barrett DA: Broccoli consumption interacts with GSTM1 to perturb oncogenic signalling pathways in the prostate. PLoS ONE. 2008, 3: e2568- 10.1371/journal.pone.0002568PubMedCentralCrossRefPubMed
14.
Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS: Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003, 4: 209-221. 10.1016/S1535-6108(03)00215-0CrossRefPubMed
15.
Uzgare AR, Isaacs JT: Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res. 2004, 64: 6190-6199. 10.1158/0008-5472.CAN-04-0968CrossRefPubMed
16.
Laajala E, Aittokallio T, Lahesmaa R, Elo LL: Probe-level estimation improves the detection of differential splicing in Affymetrix exon array studies. Genome Biol. 2009, 10: R77- 10.1186/gb-2009-10-7-r77PubMedCentralCrossRefPubMed
17.
Purdom E, Simpson KM, Robinson MD, Conboy JG, Lapuk AV, Speed TP: FIRMA: a method for detection of alternative splicing from exon array data. Bioinformatics. 2008, 24: 1707-1714. 10.1093/bioinformatics/btn284PubMedCentralCrossRefPubMed
18.
Bengtsson H, Simpson K, Bullard J, Hansen K: aroma.affymetrix: A generic framework in R for analyzing small to very large Affymetrix data sets in bounded memory. Tech Report #745, Department of Statistics, University of California, Berkeley. 2008,
19.
Ligtenberg AJ, Veerman EC, Nieuw Amerongen AV, Mollenhauer J: Salivary agglutinin/glycoprotein-340/DMBT1: a single molecule with variable composition and with different functions in infection, inflammation and cancer. Biol Chem. 2007, 388: 1275-1289. 10.1515/BC.2007.158CrossRefPubMed
20.
Berquin IM, Min Y, Wu R, Wu J, Perry D, Cline JM, Thomas MJ, Thornburg T, Kulik G, Smith A: Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest. 2007, 117: 1866-1875. 10.1172/JCI31494PubMedCentralCrossRefPubMed
21.
Hu R, Khor TO, Shen G, Jeong WS, Hebbar V, Chen C, Xu C, Reddy B, Chada K, Kong AN: Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a natural product derived from cruciferous vegetable. Carcinogenesis. 2006, 27: 2038-2046. 10.1093/carcin/bgl049CrossRefPubMed
22.
Conaway CC, Wang CX, Pittman B, Yang YM, Schwartz JE, Tian D, McIntee EJ, Hecht SS, Chung FL: Phenethyl Isothiocyanate and Sulforaphane and their N-Acetylcysteine Conjugates Inhibit Malignant Progression of Lung Adenomas Induced by Tobacco Carcinogens in A/J Mice. Cancer Res. 2005, 65: 8548-8557. 10.1158/0008-5472.CAN-05-0237CrossRefPubMed
23.
Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A: Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006, 66: 1234-1240. 10.1158/0008-5472.CAN-05-1145CrossRefPubMed
24.
Kristal AR, Lampe JW: Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. Nutr Cancer. 2002, 42: 1-9. 10.1207/S15327914NC421_1CrossRefPubMed
25.
Planchon SM, Waite KA, Eng C: The nuclear affairs of PTEN. J Cell Sci. 2008, 121: 249-253. 10.1242/jcs.022459CrossRefPubMed
26.
Chang CJ, Mulholland DJ, Valamehr B, Mosessian S, Sellers WR, Wu H: PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol Cell Biol. 2008, 28: 3281-3289. 10.1128/MCB.00310-08PubMedCentralCrossRefPubMed
27.
Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, Yin Y: Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007, 128: 157-170. 10.1016/j.cell.2006.11.042CrossRefPubMed
28.
Chiao JW, Chung FL, Kancherla R, Ahmed T, Mittelman A, Conaway CC: Sulforaphane and its metabolite mediate growth arrest and apoptosis in human prostate cancer cells. Int J Oncol. 2002, 20: 631-636.PubMed
29.
Shen G, Xu C, Chen C, Hebbar V, Kong AN: p53-independent G1 cell cycle arrest of human colon carcinoma cells HT-29 by sulforaphane is associated with induction of p21CIP1 and inhibition of expression of cyclin D1. Cancer Chemother Pharmacol. 2006, 57: 317-327. 10.1007/s00280-005-0050-3CrossRefPubMed
30.
Fimognari C, Nusse M, Berti F, Iori R, Cantelli-Forti G, Hrelia P: Cyclin D3 and p53 mediate sulforaphane-induced cell cycle delay and apoptosis in non-transformed human T lymphocytes. Cell Mol Life Sci. 2002, 59: 2004-2012. 10.1007/PL00012523CrossRefPubMed
31.
Khor TO, Hu R, Shen G, Jeong WS, Hebbar V, Chen C, Xu C, Nair S, Reddy B, Chada K, Kong AN: Pharmacogenomics of cancer chemopreventive isothiocyanate compound sulforaphane in the intestinal polyps of ApcMin/+ mice. Biopharm Drug Dispos. 2006, 27: 407-420. 10.1002/bdd.522CrossRefPubMed
32.
Gamet-Payrastre L, Li P, Lumeau S, Cassar G, Dupont MA, Chevolleau S, Gasc N, Tulliez J, Terce F: Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 2000, 60: 1426-1433.PubMed
33.
Jackson SJ, Singletary KW: Sulforaphane inhibits human MCF-7 mammary cancer cell mitotic progression and tubulin polymerization. J Nutr. 2004, 134: 2229-2236.PubMed
34.
Shankar S, Ganapathy S, Srivastava RK: Sulforaphane Enhances the Therapeutic Potential of TRAIL in Prostate Cancer Orthotopic Model through Regulation of Apoptosis, Metastasis, and Angiogenesis. Clin Cancer Res. 2008, 14: 6855-6866. 10.1158/1078-0432.CCR-08-0903CrossRefPubMed
35.
Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S: Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 2002, 62: 5196-5203.PubMed
36.
Hu R, Xu C, Shen G, Jain MR, Khor TO, Gopalkrishnan A, Lin W, Reddy B, Chan JY, Kong AN: Gene expression profiles induced by cancer chemopreventive isothiocyanate sulforaphane in the liver of C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Cancer Lett. 2006, 243: 170-192. 10.1016/j.canlet.2005.11.050CrossRefPubMed
37.
Gasper AV, Traka M, Bacon JR, Smith JA, Taylor MA, Hawkey CJ, Barrett DA, Mithen RF: Consuming broccoli does not induce genes associated with xenobiotic metabolism and cell cycle control in human gastric mucosa. J Nutr. 2007, 137: 1718-1724.PubMed
38.
McCullough ML, Giovannucci EL: Diet and cancer prevention. Oncogene. 2004, 23: 6349-6364. 10.1038/sj.onc.1207716CrossRefPubMed
39.
Khan N, Afaq F, Mukhtar H: Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal. 2008, 10: 475-510. 10.1089/ars.2007.1740CrossRefPubMed
40.
Chen LH, Fang J, Sun Z, Li H, Wu Y, Demark-Wahnefried W, Lin X: Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells. J Nutr. 2009, 139: 653-659. 10.3945/jn.108.101832PubMedCentralCrossRefPubMed
41.
Hou DX, Kumamoto T: Flavonoids as Protein Kinase Inhibitors for Cancer Chemoprevention: Direct Binding and Molecular Modeling. Antioxid Redox Signal. 2010, ,
42.
Stamm S, Ben-Ari S, Rafalska I, Tang Y, Zhang Z, Toiber D, Thanaraj TA, Soreq H: Function of alternative splicing. Gene. 2005, 344: 1-20. 10.1016/j.gene.2004.10.022CrossRefPubMed
43.
Stamm S: Regulation of alternative splicing by reversible protein phosphorylation. J Biol Chem. 2008, 283: 1223-1227. 10.1074/jbc.R700034200CrossRefPubMed
44.
Novoyatleva T, Heinrich B, Tang Y, Benderska N, Butchbach ME, Lorson CL, Lorson MA, Ben-Dov C, Fehlbaum P, Bracco L: Protein phosphatase 1 binds to the RNA recognition motif of several splicing factors and regulates alternative pre-mRNA processing. Hum Mol Genet. 2008, 17: 52-70. 10.1093/hmg/ddm284CrossRefPubMed
45.
Patel NA, Kaneko S, Apostolatos HS, Bae SS, Watson JE, Davidowitz K, Chappell DS, Birnbaum MJ, Cheng JQ, Cooper DR: Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase CbetaII alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40. J Biol Chem. 2005, 280: 14302-14309. 10.1074/jbc.M411485200CrossRefPubMed
46.
Blaustein M, Pelisch F, Coso OA, Bissell MJ, Kornblihtt AR, Srebrow A: Mammary epithelial-mesenchymal interaction regulates fibronectin alternative splicing via phosphatidylinositol 3-kinase. J Biol Chem. 2004, 279: 21029-21037. 10.1074/jbc.M314260200CrossRefPubMed
47.
Jiang K, Patel NA, Watson JE, Apostolatos H, Kleiman E, Hanson O, Hagiwara M, Cooper DR: Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phosphorylation, and insulin-induced alternative splicing of PKCbetaII messenger ribonucleic acid. Endocrinology. 2009, 150: 2087-2097. 10.1210/en.2008-0818PubMedCentralCrossRefPubMed
48.
Gardina PJ, Clark TA, Shimada B, Staples MK, Yang Q, Veitch J, Schweitzer A, Awad T, Sugnet C, Dee S: Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics. 2006, 7: 325- 10.1186/1471-2164-7-325PubMedCentralCrossRefPubMed
49.
Thorsen K, Sorensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AM, Kruhoffer M, Laurberg S, Borre M, Wang K: Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics. 2008, 7: 1214-1224. 10.1074/mcp.M700590-MCP200CrossRefPubMed
50.
Shibata T, Nakahara H, Kita N, Matsubara Y, Han C, Morimitsu Y, Iwamoto N, Kumagai Y, Nishida M, Kurose H: A food-derived synergist of NGF signaling: identification of protein tyrosine phosphatase 1B as a key regulator of NGF receptor-initiated signal transduction. J Neurochem. 2008, 107: 1248-1260. 10.1111/j.1471-4159.2008.05686.xCrossRefPubMed
51.
Mollenhauer J, Herbertz S, Holmskov U, Tolnay M, Krebs I, Merlo A, Schroder HD, Maier D, Breitling F, Wiemann S: DMBT1 encodes a protein involved in the immune defense and in epithelial differentiation and is highly unstable in cancer. Cancer Res. 2000, 60: 1704-1710.PubMed
52.
Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009, 9: 550-562. 10.1038/nrc2664CrossRefPubMed
53.
54.
Ratnacaram CK, Teletin M, Jiang M, Meng X, Chambon P, Metzger D: Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc Natl Acad Sci USA. 2008, 105: 2521-2526. 10.1073/pnas.0712021105PubMedCentralCrossRefPubMed
55.
Luchman HA, Benediktsson H, Villemaire ML, Peterson AC, Jirik FR: The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision. PLoS One. 2008, 3: e3940- 10.1371/journal.pone.0003940PubMedCentralCrossRefPubMed
56.
Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, Sangiorgi FO, Maxson RE, Sucov HM, Roy-Burman P: Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev. 2001, 101: 61-69. 10.1016/S0925-4773(00)00551-7CrossRefPubMed
57.
Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X, Wu H: Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis. 2002, 32: 148-149. 10.1002/gene.10036CrossRefPubMed
58.
Mithen R, Faulkner K, Magrath R, Rose P, Williamson G, Marquez J: Development of isothiocyanate-enriched broccoli, and its enhanced ability to induce phase 2 detoxification enzymes in mammalian cells. Theor Appl Genet. 2003, 106: 727-734.PubMed
59.
Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R: Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 2004, 64: 2270-2305. 10.1158/0008-5472.CAN-03-0946CrossRefPubMed
60.
Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5: R80- 10.1186/gb-2004-5-10-r80PubMedCentralCrossRefPubMed
61.
Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004, 3: Article3-PubMed
62.
Durinck S, Bullard J, Spellman PT, Dudoit S: GenomeGraphs: integrated genomic data visualization with R. BMC Bioinformatics. 2009, 10: 2- 10.1186/1471-2105-10-2PubMedCentralCrossRefPubMed
63.
Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR: GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat Genet. 2002, 31: 19-20. 10.1038/ng0502-19CrossRefPubMed
64.
Huang da W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009, 4: 44-57. 10.1038/nprot.2008.211CrossRefPubMed
65.
Metadata
Title
The dietary isothiocyanate sulforaphane modulates gene expression and alternative gene splicing in a PTEN null preclinical murine model of prostate cancer
Authors
Maria H Traka
Caroline A Spinks
Joanne F Doleman
Antonietta Melchini
Richard Y Ball
Robert D Mills
Richard F Mithen
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-189

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Review

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

Review

Convergence between Wnt-β-catenin and EGFR signaling in cancer

Research

NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3

Research

Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B)

Research

RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma

Research

Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits